- Bringing it closer to becoming a global top 10 drugmaker, Takeda Pharmaceutical (TKPYY) has received approval from China's market regulator for its $62B acquisition of Shire (NASDAQ:SHPG).
- The deal, which will be the largest overseas purchase by a Japanese company, has already received unconditional clearance from regulators in the U.S. and Brazil and awaits approval from Japan and the EU.
- SHPG +1.6% premarket